CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus

NCT06349343 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology